Research methodologies to address clinical unmet needs and challenges in alcohol‐associated liver disease

Singal, Ashwani K.; Kwo, Paul Y.; Kwong, Allison J.; Liangpunsakul, Suthat; Louvet, Alexandre; Mandrekar, Pranoti; McClain, Craig J.; Mellinger, Jessica L.; Szabó, Gyöngyi; Terrault, Norah A.; Thursz, Mark; Winder, Gerald Scott; Kim, W. Ray; Shah, Vijay H.

doi:10.1002/hep.32143

Cited by 23 publications

(32 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While pharmacological and behavioral interventions remain the cornerstone of management at the individual level, specific public health policies for effective control of excessive alcohol use and its overall impact are needed. Future analyses and studies focusing on local regulations, socioeconomic and cultural factors influencing excessive alcohol use may be required to devise better policies at the population level to reduce alcohol-related mortality and morbidity effectively and thus reduce the global burden of disease (83). J o u r n a l P r e -p r o o f…”

Section: Discussionmentioning

confidence: 99%

Epidemiology and Disease Burden of Alcohol Associated Liver Disease

Aslam

Kwo²

2023

Journal of Clinical and Experimental Hepatology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Epidemiology and Disease Burden of Alcohol Associated Liver Disease

Aslam

Kwo²

2023

Journal of Clinical and Experimental Hepatology

View full text Add to dashboard Cite

“…Efforts to bend the epidemiologic curves downward for women, minorities, young people, and, indeed, all people with ALD depend on strong public health efforts to reduce population-level alcohol use and to increase access to evidence-based AUD treatment. [81][82][83]…”

Section: Discussionmentioning

confidence: 99%

The Changing Epidemiology of Alcohol-Associated Liver Disease: Gender, Race, and Risk Factors

Anouti

Mellinger

2022

Semin Liver Dis

View full text Add to dashboard Cite

Cases of alcohol-associated liver disease (ALD) are increasing at a steady rate in the United States with more patients presenting with alcohol-associated hepatitis (AH) and alcohol-associated cirrhosis (AC). While alcohol use has increased across many demographic groups, women are suffering from a greater increase in alcohol use disorder (AUD), and are at a greater risk of ALD due to pathophysiological differences which include absorption of alcohol, first pass metabolism, and hormonal differences. Differences across race have also been found with Native Americans and Hispanics suffering from some of the largest increases in ALD rates. Younger adults are heavily impacted by rising rates of both AUD and ALD. Comorbidities such as obesity and NASH have been shown to augment the deleterious effects of AUD and ALD, resulting in more advanced liver disease. Finally, COVID-19 and policies related to the pandemic have resulted in increased AUD across many cohorts, which has itself resulted in marked increases in ALD. In conclusion, ALD rates are rising, with young people and women particularly impacted.

show abstract

“…To date, despite medical developments in knowledge and drug treatments, liver transplantation (LT) remains the only curative treatment option for selected patients with acute liver failure, end-stage liver disease (ESLD), liver cancer and acquired or genetic metabolic liver disease[ 1 ]. ESLD is the most frequent indication for LT with alcohol-related liver disease as the main etiology[ 2 ]. Other common etiologies are metabolic dysfunction-associated fatty liver disease (MAFLD) and viral hepatitis[ 3 , 4 ].…”

Section: Introductionmentioning

confidence: 99%

Improving the prognosis before and after liver transplantation: Is muscle a game changer?

Goffaux¹,

Delorme²,

Dahlqvist³

et al. 2022

World J Gastroenterol

View full text Add to dashboard Cite

Liver transplantation (LT) is currently the only curative treatment option for selected patients with end stage liver disease or hepatocellular carcinoma. Improving waiting list-mortality, post-transplant morbidity and mortality and refining the selection of the patients remain our current central objectives. In this field, different concepts dealing with nutrition and the muscle such as sarcopenia, malnutrition, frailty or myosteatosis have emerged as possible game changers. For more than a decade, many prospective studies have demonstrated that sarcopenia and frailty are major predictive factors of mortality in the waiting list but also after LT. Malnutrition is also a well-known risk factor for morbidity and mor-tality. Muscle composition is a newer concept giving insight on muscle quality which has also been shown to be linked to poorer outcomes. Each of these terms has a precise definition as well as pathophysiological mechanisms. The bi-directional liver-muscle axis makes sense in this situation. Defining the best, easy to use in clinical practice tools to assess muscle quality, quantity, and function in this specific population and developing quality prospective studies to identify interventional strategies that could improve these parameters as well as evaluate the effect on mortality are among the important challenges of today.

show abstract

Research methodologies to address clinical unmet needs and challenges in alcohol‐associated liver disease

Cited by 23 publications

References 71 publications

Epidemiology and Disease Burden of Alcohol Associated Liver Disease

Epidemiology and Disease Burden of Alcohol Associated Liver Disease

The Changing Epidemiology of Alcohol-Associated Liver Disease: Gender, Race, and Risk Factors

Improving the prognosis before and after liver transplantation: Is muscle a game changer?

Contact Info

Product

Resources

About